LOS ANGELES and KYOTO, Japan, April 11, 2011 /PRNewswire/ --
ImaginAb, Inc. and Dainippon Seiki Co., Ltd. have concluded
a technology agreement around the development of automated
chemistry systems for fluorination of proteins and peptides for
diagnostic imaging with positron emission tomography
(PET).

"Over the past 18 months, our academic and pharma client base
has dramatically increased and we have been developing and
in-licensing novel fluorine chemistries to streamline labeling of
proteins and peptides for targeted molecular imaging with PET,"
said Dr. Christian Behrenbruch, CEO of ImaginAb. "DNS has
tremendous automation and instrumentation experience in the
chemistry / radiochemistry domain and we are delighted to be
working with such a dynamic and innovative organization to deliver
new solutions to our customers."

Mr. Masayoshi Sugihara, President of DNS commented, "We have
seen a significant increase in the interest level in novel peptides
and biologics for diagnostic imaging and believe in the
commercial importance of automated fluorine chemistry to drive this
industry ahead. We are pleased to be collaborating with
ImaginAb to develop high-throughput fluorination solutions
that will be suitable for both pre-clinical and (eventually)
clinical use."*

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and
Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company
specializing in the development of engineered antibody fragments
for diagnostic imaging and novel therapeutic applications. The
company has a significant pipeline of clinical products in
development oriented towards unmet needs in cancer and immunology.
ImaginAb is also developing a range of pre-clinical (animal
imaging) reagents for use with microPET, microSPECT and optical
imaging systems, and partners on a selective basis with
biopharmaceutical companies with an interest in developing co